PMID- 17143264
OWN - NLM
STAT- MEDLINE
DCOM- 20070406
LR  - 20230210
IS  - 0893-3952 (Print)
IS  - 0893-3952 (Linking)
VI  - 20
IP  - 1
DP  - 2007 Jan
TI  - Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma 
      of the esophagus.
PG  - 120-9
AB  - HER-2 is the target for antibody based treatment of breast cancer (Herceptin). In 
      order to evaluate the potential role of such a treatment in esophageal cancers, 
      HER-2 amplification and overexpression was investigated in primary and metastatic 
      cancers of the esophagus. A tissue microarray was constructed from 255 primary 
      esophageal cancers (110 adenocarcinomas and 145 squamous cell carcinomas), 89 
      nodal and 33 distant metastases. Slides were analyzed by immunohistochemistry 
      (HercepTest; DAKO) and fluorescence in situ hybridization (FISH; PathVysion; 
      Vysis-Abbott) for HER-2 amplification and overexpression. Amplification was seen 
      in 16/110 (15%) adenocarcinomas and in 7/145 (5%) squamous cell carcinomas. There 
      was a strong association between HER-2 amplification and overexpression, 
      especially in adenocarcinomas (P<0.0001, log rank). There was a 100% concordance 
      of the HER-2 results in primary tumor and corresponding metastases in 84 analyzed 
      pairs. Amplification was typically high-level with more than 10-15 HER-2 copies 
      per tumor cell. Amplification was unrelated to survival, grading, pT, pN, pM or 
      UICC stage. We conclude that esophageal adenocarcinomas belong to those cancer 
      types with relevant frequency high-level HER-2 gene amplification clinical trials 
      or individual case studies investigating the response of metastatic 
      HER-2-positive esophageal cancers to Herceptin((R)) should be undertaken. The 
      strong concordance of the HER-2 status in primary and metastatic cancers argues 
      for a possible response of metastases from patients with HER-2-positive primary 
      tumors to Herceptin.
FAU - Reichelt, Uta
AU  - Reichelt U
AD  - Department of Pathology, University Medical Center Hamburg-Eppendorf, University 
      of Hamburg, Hamburg, Germany.
FAU - Duesedau, Peer
AU  - Duesedau P
FAU - Tsourlakis, Maria Ch
AU  - Tsourlakis MCh
FAU - Quaas, Alexander
AU  - Quaas A
FAU - Link, Bjorn C
AU  - Link BC
FAU - Schurr, Paulus G
AU  - Schurr PG
FAU - Kaifi, Jussuf T
AU  - Kaifi JT
FAU - Gros, Stephanie J
AU  - Gros SJ
FAU - Yekebas, Emre F
AU  - Yekebas EF
FAU - Marx, Andreas
AU  - Marx A
FAU - Simon, Ronald
AU  - Simon R
FAU - Izbicki, Jakob R
AU  - Izbicki JR
FAU - Sauter, Guido
AU  - Sauter G
LA  - eng
PT  - Journal Article
DEP - 20061124
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/chemistry/genetics/*pathology/secondary
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/chemistry/genetics/*pathology/secondary
MH  - Esophageal Neoplasms/chemistry/genetics/*pathology/secondary
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Amplification
MH  - *Gene Expression Regulation, Neoplastic
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Matched-Pair Analysis
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Receptor, ErbB-2/*analysis
MH  - Time Factors
MH  - Tissue Array Analysis
MH  - Up-Regulation
EDAT- 2006/12/05 09:00
MHDA- 2007/04/07 09:00
CRDT- 2006/12/05 09:00
PHST- 2006/12/05 09:00 [pubmed]
PHST- 2007/04/07 09:00 [medline]
PHST- 2006/12/05 09:00 [entrez]
AID - S0893-3952(22)01680-5 [pii]
AID - 10.1038/modpathol.3800712 [doi]
PST - ppublish
SO  - Mod Pathol. 2007 Jan;20(1):120-9. doi: 10.1038/modpathol.3800712. Epub 2006 Nov 
      24.